JPH0624976A - Composition for transfusion solution - Google Patents
Composition for transfusion solutionInfo
- Publication number
- JPH0624976A JPH0624976A JP18410792A JP18410792A JPH0624976A JP H0624976 A JPH0624976 A JP H0624976A JP 18410792 A JP18410792 A JP 18410792A JP 18410792 A JP18410792 A JP 18410792A JP H0624976 A JPH0624976 A JP H0624976A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- blood
- infusion
- mol
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は輸液用組成物に関し、さ
らに詳しくは、スズメバチ（Vespa 属）の幼虫が分泌す
るだ液中に含まれているアミノ酸類で構成されるアミノ
酸組成物を有効成分とし、脂質及び糖質代謝調節作用を
有する輸液用組成物に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a composition for infusion, more specifically, an amino acid composition composed of amino acids contained in saliva secreted by a larva of wasp ( Vespa genus) as an active ingredient. And a composition for infusion having a lipid and sugar metabolism regulating action.
【従来の技術】従来、スズメバチの幼虫に関する報告、
特に幼虫が分泌するだ液に関する報告はほとんどなく、
その組成は全く解明されていなかった。またスズメバチ
の驚異的な筋持続力はどの様な栄養に由来するのかも不
明であった。本発明者らは、種々のスズメバチの幼虫が
分泌するだ液について研究し、その組成を明らかにする
とともに、その組成物が極めて有効な脂質及び糖質代謝
調節作用を有することを見出し、その有効成分を解明し
てきた。スズメバチの幼虫が分泌するアミノ酸栄養液
は、経口投与により運動時の脂質及び糖質代謝を調節す
ることが明らかになっている（特願平１−１５０７８８
号、特願平２−２１０８９５号、特願平２−２３２９７
７号、特願平２−２４０９６１号）。2. Description of the Related Art Conventionally, reports on larvae of hornets,
There are few reports on saliva secreted by larvae,
Its composition has never been elucidated. It was also unclear what nutrition originated from the muscular endurance of wasps. The present inventors have studied the saliva secreted by various hornet larvae, clarified its composition, found that the composition has an extremely effective lipid and carbohydrate metabolism regulating action, and The ingredients have been clarified. It has been clarified that the amino acid nutrient solution secreted by hornet larvae regulates lipid and sugar metabolism during exercise by oral administration (Japanese Patent Application No. 1-1508788).
Japanese Patent Application No. 2-210895, Japanese Patent Application No. 2-23297
No. 7, Japanese Patent Application No. 2-240961).
【０００２】[0002]
【発明が解決しようとする課題】しかしながら、上記の
アミノ酸組成物（以下ＶＡＡＭと略す）を経口的に投与
しても、血中の遊離脂肪酸（以下ＮＥＦＡと略す）濃度
は直ちに上昇せず、作用が遅効性であるという問題があ
った。また、ＶＡＡＭを直接血中に投与した場合の作用
については、何ら明らかにされておらず、静脈投与にお
ける生物体の静止時に優れた即効作用のある輸液の調整
もなされていなかった。However, even if the above amino acid composition (hereinafter abbreviated as VAAM) is orally administered, the concentration of free fatty acid (hereinafter abbreviated as NEFA) in blood does not immediately increase, and the action Has a problem of being slow-acting. In addition, the effect of direct administration of VAAM into blood has not been clarified at all, and no preparation of an infusion solution having an excellent immediate effect when an organism is stationary during intravenous administration has not been prepared.
【課題を解決するための手段】本発明者は、種々のスズ
メバチの幼虫が分泌するだ液に含まれる組成物の組成に
ついて鋭意研究した結果、スレオニン、プロリン、グリ
シン、バリン、イソロイシン、ロイシン、チロシン、フ
ェニルアラニン、リジン、メチオニン、トリプトファ
ン、ヒスチジン、及びアルギニンを有効成分とするアミ
ノ酸組成物を輸液として経静脈的に投与すると、カゼイ
ンアミノ酸組成物（ＣＡＡＭ）に比べてＶＡＡＭの組成
に近いと言われている人乳アミノ酸組成物を経口投与し
た場合に比べて、血中のＮＥＦＡが著しく増加し、血中
乳酸及び血中ピルビン酸が有効に制御されること、なら
びにこれらの作用の発現が即効性であることを見出し
た。また、上記のアミノ酸組成物にさらにアスパラギン
酸、セリン、グルタミン酸、及びアラニンを添加した組
成物、又はこの組成物にさらにタウリン、β−アラニ
ン、γ−アミノ酪酸、エタノールアミン、アンモニア、
オルニチン、１−メチルヒスチジン、及び３−メチルヒ
スチジンを添加した組成物も輸液用組成物として有用で
あることを見出した。Means for Solving the Problems As a result of earnest studies on the composition of a composition contained in saliva secreted by various hornet larvae, the present inventor has found that threonine, proline, glycine, valine, isoleucine, leucine and tyrosine. It is said that when an amino acid composition containing phenylalanine, lysine, methionine, tryptophan, histidine, and arginine as an active ingredient is intravenously administered as an infusion solution, the composition is closer to that of VAAM than the casein amino acid composition (CAAM). Compared with oral administration of human milk amino acid composition, blood NEFA is significantly increased, blood lactic acid and blood pyruvate are effectively controlled, and the onset of these effects is immediate. I found that there is. Further, aspartic acid, serine, glutamic acid, and alanine are further added to the above amino acid composition, or taurine, β-alanine, γ-aminobutyric acid, ethanolamine, ammonia is further added to this composition.
It has been found that a composition containing ornithine, 1-methylhistidine, and 3-methylhistidine is also useful as a composition for infusion.
【０００３】本発明の輸液組成物は、好ましくはスレオ
ニン(Thr) を２〜１５モル、プロリン（Pro)を４〜３０
モル、グリシン(Gly) を７〜２０モル、バリン(Val) を
４〜８モル、イソロイシン(I-Leu) を３〜９モル、ロイ
シン(Leu) を２〜１２モル、チロシン(Try) を１〜９モ
ル、フェニルアラニン(Phe) を0.５〜５モル、リジン(L
ys) を５〜１１モルの割合で含有し、かつそれぞれ５モ
ル以下の割合でメチオニン(Met) 、トリプトファン(Tr
p) 、ヒスチジン(His) 、アルギニン(Arg) を含有す
る。その他に３モル以下の割合のタウリン(Tau) 、２モ
ル以下の割合のリン酸エタノールアミン(P-EtAm)、１モ
ル以下の割合のアスパラギン酸(Asp) 、５モル以下の割
合のアスパラギン(Asn) 又はセリン(Ser) 、４モル以下
の割合のグルタミン酸(Glu) 、１２モル以下の割合のア
ラニン(Ala) 、0.５モル以下の割合のシスチン(Cys) 、
１モル以下の割合のβ−アラニン (β-Ala) 、0.５モル
以下の割合のγ−アミノ酪酸(GABA)、３モル以下の割合
のオルニチン(Orn) 又はエタノールアミン(EtAm)、２モ
ル以下の割合のアンモニア(NH3) 、３モル以下の割合の
1-メチルヒスチジン(1-MeHis) 、１モル以下の割合の3-
メチルヒスチジン(3-MeHis) を含むことができる。The infusion composition of the present invention preferably contains 2 to 15 mol of threonine (Thr) and 4 to 30 proline (Pro).
Mol, glycine (Gly) 7 to 20 mol, valine (Val) 4 to 8 mol, isoleucine (I-Leu) 3 to 9 mol, leucine (Leu) 2 to 12 mol, tyrosine (Try) 1 ~ 9 mol, phenylalanine (Phe) 0.5 to 5 mol, lysine (L
ys) in an amount of 5 to 11 mol, and methionine (Met) and tryptophan (Tr) in an amount of 5 mol or less, respectively.
p), histidine (His) and arginine (Arg). In addition, 3 mol or less of taurine (Tau), 2 mol or less of ethanolamine phosphate (P-EtAm), 1 mol or less of aspartic acid (Asp), 5 mol or less of asparagine (Asn). ) Or serine (Ser), 4 mol or less of glutamic acid (Glu), 12 mol or less of alanine (Ala), 0.5 mol or less of cystine (Cys),
1 mol or less of β-alanine (β-Ala), 0.5 mol or less of γ-aminobutyric acid (GABA), 3 mol or less of ornithine (Orn) or ethanolamine (EtAm), 2 mol Ammonia (NH 3 ) in proportions below
1-Methylhistidine (1-MeHis), 1 mol or less of 3-
Methylhistidine (3-MeHis) can be included.
【０００４】本発明の輸液用組成物の一態様によれば、
スレオニンを約6.３モル、プロリンを約１5.８モル、グ
リシンを約１6.８モル、バリンを約5.１モル、イソロイ
シンを約4.０モル、ロイシンを約5.４モル、チロシンを
約5.２モル、フェニルアラニンを約3.４モル、リジンを
約7.６モル、メチオニンを約0.４７モル、トリプトファ
ンを約1.９モル、ヒスチジンを約2.３モル、及びアルギ
ニンを約3.１モルの割合で含む輸液用組成物が提供され
る。また、さらにアスパラギン酸を約0.１４モル、セリ
ンを約2.２モル、グルタミン酸を約2.８モル、及びアラ
ニンを約5.３モルの割合で含む輸液用組成物も提供され
る。本発明の輸液用組成物の例を、以下の表１に示す。
表中、キイロはキイロスズメバチ(Vespa xanthoptera)
由来の組成物、モンはモンスズメバチ(Vespa crabro)由
来の組成物、ヒメはヒメスズメバチ(Vespa tropica) 由
来の組成物、コガタはコガタスズメバチ(Vespa analis)
由来の組成物、オオはオオスズメバチ(Vespamandarini
a)由来の組成物（各々、分析値を示す）を示し、またＶ
ＡＡＭは本発明の輸液組成物の一態様を示したものであ
る。According to one aspect of the composition for infusion according to the present invention,
About 6.3 moles of threonine, about 15.8 moles of proline, about 16.8 moles of glycine, about 5.1 moles of valine, about 4.0 moles of isoleucine, about 5.4 moles of leucine and tyrosine. About 5.2 moles, phenylalanine about 3.4 moles, lysine about 7.6 moles, methionine about 0.47 moles, tryptophan about 1.9 moles, histidine about 2.3 moles, and arginine about. A composition for infusion is provided, which is included in a ratio of 3.1 mol. Also provided is an infusion composition further comprising aspartic acid in an amount of about 0.14 mol, serine in an amount of about 2.2 mol, glutamic acid in an amount of about 2.8 mol, and alanine in an amount of about 5.3 mol. Examples of the composition for infusion of the present invention are shown in Table 1 below.
In the table, yellow is a yellow hornet (Vespa xanthoptera ).
Derived from the composition, Mon is a composition derived from the hornet (Vespa crabro) , Hime is a composition derived from a female hornet (Vespa tropica ), and Kogata is a hornet (Vespa analis).
The composition of origin, the giant hornet (Vespa mandarini)
The composition derived from a) (each showing an analytical value) is shown, and V
AAM shows one aspect of the infusion composition of the present invention.
【０００５】[0005]
【表１】 （含有率モル％） ──────────────────────────────────── アミノ酸 キイロ モ ン ヒ メ コガタ オ オ ＶＡＡＭ＊ ──────────────────────────────────── Tau 0.8 2.1 0.7 2.1 0.5 P-EtAm 1.1 Asp 0.1 0.1 0.1 0.1 0.2 0.14 Thr 3.1 10.4 13.0 8.5 6.5 6.31 Ser 4.3 2.3 2.8 4.7 2.4 2.17 Asn 0.6 0.5 3.8 Glu 1.0 0.5 1.0 2.3 3.0 2.81 Pro 21.7 6.4 5.1 28.5 17.1 15.82 Gly 12.2 12.1 17.3 8.8 18.2 16.77 Ala 10.4 4.5 4.8 8.0 5.7 5.30 Val 7.0 6.6 6.6 5.2 5.6 5.13 Cys 0.1 0.1 Met 0.6 0.6 1.0 0.2 0.6 0.47 I-Leu 4.4 7.5 5.8 4.1 4.3 3.97 Leu 5.7 10.5 8.5 3.1 5.8 5.40 Tyr 3.7 5.9 7.7 2.0 5.7 5.23 Phe 3.2 4.3 5.2 1.7 3.7 3.37 β-Ala 0.3 0.7 0.2 0.4 0.2 GABA 0.1 0.2 0.1 0.4 0.3 EtAm 1.9 2.4 0.9 0.6 1.0 NH3 0.7 0.9 0.7 1.7 1.1 Orn 1.5 2.4 0.9 0.8 1.0 Lys 8.6 9.6 7.2 6.3 8.2 7.56 Trp 1.2 3.4 3.1 1.3 2.1 1.93 His 2.6 2.6 3.2 2.5 2.5 2.26 1-MeHis 0.4 3-MeHis 0.5 Arg 3.5 4.1 3.6 3.1 3.3 3.09 ──────────────────────────────────── ＊ 成分モル比で示す。[Table 1] (Content mol%) ──────────────────────────────────── Amino acid Himegatagata Oh VAAM * ──────────────────────────────────── Tau 0.8 2.1 0.7 2.1 0.5 P -EtAm 1.1 Asp 0.1 0.1 0.1 0.1 0.2 0.14 Thr 3.1 10.4 13.0 8.5 6.5 6.31 Ser 4.3 2.3 2.8 4.7 2.4 2.17 Asn 0.6 0.5 3.8 Glu 1.0 0.5 1.0 2.3 3.0 2.81 Pro 21.7 6.4 5.1 28.5 17.1 15.82 Gly 12.2 12.1 17.3 8.8 18.2 16.77 Ala 10.4 4.5 4.8 8.0 5.7 5.30 Val 7.0 6.6 6.6 5.2 5.6 5.13 Cys 0.1 0.1 Met 0.6 0.6 1.0 0.2 0.6 0.47 I-Leu 4.4 7.5 5.8 4.1 4.3 3.97 Leu 5.7 10.5 8.5 3.1 5.8 5.40 Tyr 3.7 5.9 7.7 2.0 5.7 5.23 Phe 3.2 4.3 5.2 1.7 3.7 3.37 β-Ala 0.3 0.7 0.2 0.4 0.2 GABA 0.1 0.2 0.1 0.4 0.3 EtAm 1.9 2.4 0.9 0.6 1.0 NH 3 0.7 0.9 0.7 1.7 1.1 Orn 1.5 2.4 0.9 0.8 1.0 Lys 8.6 9.6 7.2 6.3 8.2 7.56 Trp 1.2 3.4 3.1 1.3 2.1 1.93 His 2.6 2.6 3.2 2.5 2.5 2.26 1-M eHis 0.4 3-MeHis 0.5 Arg 3.5 4.1 3.6 3.1 3.3 3.09 ──────────────────────────────────── * The molar ratio of components is shown.
【表２】 [Table 2]
【０００６】実験は下記の要領で実施した。 動物： ニュージーランドホワイト種 ウサギ（３kg）
餌料はＲＣ４（オリエンタル酵母製）を使用、室温２４
℃、湿度６５％で飼育。 試料： スズメバチアミノ酸だ液ＶＡＡＭ（表１）
0.９％ 人乳アミノ酸組成物（表２に記載のもの） 0.９％ 投与方法： 試料投与前に２０時間絶食したウサギに、
Dismic ２５フィルターでろ過滅菌した0.９％の試料溶
液を、耳静脈より５mlあるいは１０ml投与した。 採血方法： 採血は、ウサギ耳静脈から、投与前、投与
後１５分、３０分、６０分、９０分に１回につき１mlず
つ行った。血液を６％ＰＣＡで除タンパクした後、遊離
脂肪酸、血糖、乳酸、及びピルビン酸の定量を行った。 (1) 血中遊離脂肪酸の定量 検体としてＶＡＡＭ、人乳アミノ酸組成物を投与
し、耳静脈から採血を行った。 採血した血液を遠心分離して血球成分を除いた。 遠心分離後の上清について、和光純薬工業社製の臨
床試薬を用いて、脂肪酸定量を常法により行った。脂肪
酸の定量は、アシル−ＣｏＡ合成酵素とアシル−ＣｏＡ
オキシダーゼの作用により生じた過酸化水素を、ペルオ
キシダーゼと反応させ、エチル−Ｎ−アリニンと４−ア
ミノアンピリンにより呈色させて５５０nmで吸光度を測
定した。The experiment was carried out as follows. Animal: New Zealand White Rabbit (3kg)
RC4 (manufactured by Oriental Yeast) is used as the bait, room temperature is 24
Raised at ℃ and 65% humidity. Sample: Wasp amino acid saliva VAAM (Table 1)
0.9% Human milk amino acid composition (as described in Table 2) 0.9% Administration method: In rabbits fasted for 20 hours before sample administration,
A 0.9% sample solution sterilized by filtration with a Dismic 25 filter was administered through an ear vein in an amount of 5 ml or 10 ml. Blood collection method: Blood was collected from the rabbit ear vein 1 ml each before administration, 15 minutes, 30 minutes, 60 minutes, and 90 minutes after administration. After deproteinizing blood with 6% PCA, free fatty acids, blood sugar, lactic acid, and pyruvic acid were quantified. (1) Quantification of Free Fatty Acid in Blood VAAM and human milk amino acid composition were administered as samples, and blood was collected from the ear vein. The collected blood was centrifuged to remove blood cell components. With respect to the supernatant after centrifugation, fatty acids were quantified by a conventional method using a clinical reagent manufactured by Wako Pure Chemical Industries, Ltd. Quantification of fatty acids was performed using acyl-CoA synthase and acyl-CoA.
Hydrogen peroxide generated by the action of oxidase was reacted with peroxidase, colored with ethyl-N-alinine and 4-aminoampyline, and the absorbance was measured at 550 nm.
【０００７】反応式Reaction formula
【化１】 (2) 血中グルコーステスト 試験方法 採血した血液に６％過塩素酸を加えてタンパク質を変性
させた後、ヘキソキナーゼとグルコース−６−リン酸デ
ヒドロゲナーゼによってグルコースが６−リン酸δグル
コノラクトンに変わる時に１分子生成するＮＡＤＰＨ
を、ベーリンガー社の臨床試薬を用いて３４０nmの吸収
測定によって求めた。 (3) 血中乳酸テスト 試験方法 採血した血液に６％過塩素酸を加えてタンパク質を変性
させた後、乳酸デヒドロゲナーゼによって乳酸がピルビ
ン酸に変わるときに１分子生成するＮＡＤＨを、シグマ
社の臨床試薬を用いて３４０nmの吸収測定によって求め
た。 (4) 血中ピルビン酸の測定 採血した血液に６％過塩素酸を加えてタンパク質を変性
させた後、その上澄をNADH-Tris 溶液と混和し、この混
合物に乳酸デヒドロゲナーゼを添加して、ピルビン酸が
乳酸に変わる反応を３４０nmでの吸光度減少として測定
した。[Chemical 1] (2) Blood Glucose Test Test Method After 6% perchloric acid was added to the collected blood to denature the protein, glucose was converted to 6-phosphate δ-gluconolactone by hexokinase and glucose-6-phosphate dehydrogenase. NADPH that sometimes produces one molecule
Was determined by absorption measurement at 340 nm using Boehringer's clinical reagent. (3) Blood Lactate Test Test Method After denaturing the protein by adding 6% perchloric acid to the collected blood, NADH, which produces one molecule when lactate is converted to pyruvate by lactate dehydrogenase, is used by Sigma's clinical clinic. It was determined by absorption measurement at 340 nm using a reagent. (4) Measurement of blood pyruvate After 6% perchloric acid was added to the collected blood to denature the protein, the supernatant was mixed with NADH-Tris solution, and lactate dehydrogenase was added to this mixture. The reaction of converting pyruvic acid to lactic acid was measured as the decrease in absorbance at 340 nm.
【０００８】（実施例） １）遊離脂肪酸（ＮＥＦＡ）の変化 0.９％ＶＡＡＭ及び0.９％人乳アミノ酸組成物をろ過滅
菌し、各１０mlを耳静脈より１〜２分の間に投与した。
血中の遊離脂肪酸値は投与直前の値を１００％として１
５分、３０分、６０分そして９０分後の増加率で表し
た。検体数は、ＶＡＡＭで９（ｎ＝９）、人乳アミノ酸
組成物で９（ｎ＝９）とした（図１）。投与１５分及び
３０分で、ＶＡＡＭ投与群は人乳アミノ酸組成物投与群
に比べて、９５％以上の信頼度で有意差のある高い値を
示した。ＶＡＡＭ群のＮＥＦＡ値は３０分から６０分で
最高値を示し、９０分で下降したが、人乳アミノ酸組成
物群に比べると約３０％高い値を示した。 ２）血糖値の変化 0.９％のＶＡＡＭと人乳アミノ酸組成物を、各５mlづつ
上記と同様にしてウサギ耳静脈に投与し、血中グルコー
ス濃度を測定した。投与前の値を１００％として、投与
後１５分、３０分、６０分及び９０分の変化を表した。
ＶＡＡＭ群（ｎ＝１２）に比べて人乳アミノ酸組成物群
（ｎ＝９）は全ての測定点において９５％以上の信頼度
をもって有意に高い値が得られた（図２）。この結果
は、ＶＡＡＭ中に糖組成に関与するアミノ酸含量が少な
く、ＶＡＡＭの投与により脂肪の分解が促進し、血中遊
離脂肪酸濃度が高くなり、エネルギーとして脂肪酸が使
われるためであると考えられる。(Examples) 1) Changes in free fatty acid (NEFA) 0.9% VAAM and 0.9% human milk amino acid composition were sterilized by filtration, and 10 ml of each was administered through an ear vein for 1 to 2 minutes. did.
The free fatty acid level in the blood is 100% when the value immediately before administration is 100%.
The rate of increase was shown after 5, 30, 60 and 90 minutes. The number of samples was 9 (n = 9) for VAAM and 9 (n = 9) for the human milk amino acid composition (FIG. 1). At 15 minutes and 30 minutes after administration, the VAAM administration group showed a high value with a significant difference with a reliability of 95% or more as compared with the human milk amino acid composition administration group. The NEFA value of the VAAM group showed the highest value in 30 to 60 minutes and decreased in 90 minutes, but it was about 30% higher than that of the human milk amino acid composition group. 2) Changes in blood glucose level 0.9% of VAAM and the human milk amino acid composition were each administered to the rabbit ear vein in an amount of 5 ml in the same manner as above, and the blood glucose concentration was measured. The values before administration were taken as 100%, and changes at 15, 30, 60, and 90 minutes after administration were expressed.
Compared with the VAAM group (n = 12), the human milk amino acid composition group (n = 9) obtained a significantly high value with a reliability of 95% or more at all measurement points (FIG. 2). This result is considered to be because the content of amino acids involved in sugar composition in VAAM is low, the decomposition of fat is promoted by the administration of VAAM, the blood free fatty acid concentration is increased, and fatty acids are used as energy.
【０００９】３）血中乳酸値の変化 血糖値の変動と同時に血中乳酸値を測定したところ、Ｖ
ＡＡＭ群（ｎ＝１２）と人乳アミノ酸組成物群（ｎ＝
９）の両者とも１５分及び３０分後にその値は上昇し
た。しかし、増加の割合は人乳アミノ酸組成物群が３倍
以上高かった。６０分後には、人乳アミノ酸組成物群は
投与前の値に近づいたが、ＶＡＡＭ群は、逆に著しい低
下を示した。これは、ＶＡＡＭが運動時に血中乳酸値を
下げる作用と同じ効果と考えられる。全ての測定点で９
５％信頼度の有意差が得られた（図３）。 ４）血中ピルビン酸の変化 ５mlの0.９％ＶＡＡＭ及び人乳アミノ酸組成物を用い
て、血中乳酸及び血糖測定と併行してピルビン酸の変化
を測定した。投与前の血中ピルビン酸値を１００％と
し、投与後１５分、３０分、６０分及び９０分の変動の
割合を求めて図４に示した。ピルビン酸の変化は、乳酸
の変化と極めて類似しており、ＶＡＡＭ群（ｎ＝１２）
では、投与後若干の上昇が見られ、６０分後には投与前
の値よりも低下した。しかし、人乳アミノ酸組成物群
（ｎ＝９）では、投与直後１５分と３０分に著しく上昇
し、６０分後には投与前の値にかなり近づいた。全ての
測定点においてＶＡＡＭと人乳アミノ酸組成物の間に９
５％以上の信頼度で有意差が認められた。このような乳
酸値とピルビン酸値の変動の相似性は、ＶＡＡＭの乳酸
抑制作用がすでにピルビン酸生成の段階で行われている
ことを示している。3) Changes in blood lactate level When blood lactate level was measured at the same time as changes in blood glucose level, V
AAM group (n = 12) and human milk amino acid composition group (n =
The values increased in both 9) after 15 and 30 minutes. However, the rate of increase was 3 times or more higher in the human milk amino acid composition group. After 60 minutes, the human milk amino acid composition group approached the pre-administration value, while the VAAM group showed a marked decrease. This is considered to be the same effect that VAAM lowers the blood lactate level during exercise. 9 at all measurement points
A significant difference in 5% confidence level was obtained (Fig. 3). 4) Changes in blood pyruvate Using 5 ml of 0.9% VAAM and human milk amino acid composition, changes in pyruvate were measured in parallel with blood lactate and blood glucose measurement. The blood pyruvic acid level before administration was set to 100%, and the change rates at 15, 30, 60, and 90 minutes after administration were calculated and shown in FIG. Changes in pyruvate are very similar to those in lactate, with VAAM group (n = 12)
, A slight increase was observed after administration, and it decreased after 60 minutes from the value before administration. However, in the human milk amino acid composition group (n = 9), the values were remarkably increased at 15 minutes and 30 minutes immediately after the administration, and were considerably close to the values before the administration at 60 minutes. 9 between VAAM and human milk amino acid composition at all measurement points
A significant difference was recognized at a confidence level of 5% or more. The similarity of the fluctuations in the lactate level and the pyruvic acid level indicates that the lactic acid suppressing action of VAAM has already been performed at the stage of pyruvic acid production.
【００１０】以上の結果から、本発明の輸液用組成物を
静脈投与することにより、血中遊離脂肪酸が速効的に上
昇し、乳酸値が短時間で低下することが明らかである。
従って、本発明の輸液用組成物は、アルコールや癌によ
る肝機能障害等による血中あるいは肝臓の脂質の増加抑
制や乳酸分解機能の低下に対する改善作用に有効であ
る。なお、本発明の輸液用組成物を経静脈的に投与する
場合には、本発明の輸液用組成物を、注射用蒸留水や生
理食塩水等を用いて例えば0.８〜1.０％の濃度で含む輸
液として調製し、成人一日あたり約 100〜1,000ml を点
滴投与すればよい。本発明の輸液用組成物には、例えば
界面活性剤、ビタミン、ミネラル等を配合することもで
きる。From the above results, it is clear that intravenous administration of the composition for infusion according to the present invention rapidly increases blood free fatty acid and decreases lactic acid level in a short time.
Therefore, the composition for infusion according to the present invention is effective in suppressing an increase in lipids in blood or liver due to liver dysfunction caused by alcohol or cancer, and an effect of improving a decrease in lactate decomposition function. In the case of intravenously administering the composition for infusion of the present invention, the composition for infusion of the present invention is used, for example, in an amount of 0.8 to 1.0% by using distilled water for injection or physiological saline. It may be prepared as an infusion solution containing the above concentration, and about 100 to 1,000 ml per day for an adult may be infused. The composition for infusion of the present invention can also be mixed with, for example, a surfactant, vitamins, minerals and the like.
【発明の効果】本発明の輸液用組成物は、経口投与より
も少量で遊離脂肪酸の上昇あるいは乳酸値の上昇阻止に
速効性があるので有用である。INDUSTRIAL APPLICABILITY The composition for infusion according to the present invention is useful because it has a rapid effect on the elevation of free fatty acid or the elevation of lactic acid level in a smaller amount than oral administration.
【図１】本発明の輸液用組成物による遊離脂肪酸の変化
を示す図である。FIG. 1 is a diagram showing changes in free fatty acids by the composition for infusion according to the present invention.
【図２】本発明の輸液用組成物による血糖値の変化を示
す図である。FIG. 2 is a diagram showing changes in blood glucose level by the composition for infusion according to the present invention.
【図３】本発明の輸液用組成物による血中乳酸値の変化
を示す図である。FIG. 3 is a graph showing changes in blood lactate level by the composition for infusion according to the present invention.
【図４】本発明の輸液用組成物による血中ピルビン酸の
変化を示す図である。FIG. 4 is a graph showing changes in blood pyruvic acid by the composition for infusion of the present invention.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 ＦＩ 技術表示箇所 // Ａ６１Ｋ 35/64 7431−4Ｃ (72)発明者 山崎 研一 東京都千代田区大手町２丁目６番３号 新 日本製鐵株式会社内─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 5 Identification number Internal reference number FI Technical indication location // A61K 35/64 7431-4C (72) Inventor Kenichi Yamazaki 2-6 Otemachi, Chiyoda-ku, Tokyo No. 3 within Nippon Steel Corporation
Claims (3)
用組成物であって、スレオニン、プロリン、グリシン、
バリン、イソロイシン、ロイシン、チロシン、フェニル
アラニン、リジン、メチオニン、トリプトファン、ヒス
チジン、及びアルギニンを有効成分とする組成物。1. A composition for infusion having a lipid and sugar metabolism regulating effect, which comprises threonine, proline, glycine,
A composition containing valine, isoleucine, leucine, tyrosine, phenylalanine, lysine, methionine, tryptophan, histidine, and arginine as active ingredients.
ミン酸、及びアラニンを有効成分とする請求項１記載の
輸液用組成物。2. The infusion composition according to claim 1, further comprising aspartic acid, serine, glutamic acid, and alanine as active ingredients.
ミノ酪酸、エタノールアミン、アンモニア、オルニチ
ン、１−メチルヒスチジン、及び３−メチルヒスチジン
を有効成分とする請求項２記載の輸液用組成物。3. The infusion composition according to claim 2, which further comprises taurine, β-alanine, γ-aminobutyric acid, ethanolamine, ammonia, ornithine, 1-methylhistidine, and 3-methylhistidine as active ingredients.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18410792A JPH0624976A (en) | 1992-07-10 | 1992-07-10 | Composition for transfusion solution |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18410792A JPH0624976A (en) | 1992-07-10 | 1992-07-10 | Composition for transfusion solution |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0624976A true JPH0624976A (en) | 1994-02-01 |
Family
ID=16147515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP18410792A Pending JPH0624976A (en) | 1992-07-10 | 1992-07-10 | Composition for transfusion solution |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0624976A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998006278A1 (en) * | 1996-08-12 | 1998-02-19 | Harris, Roger | Methods and compositions for increasing the anaerobic working capacity in tissues |
| US5965596A (en) * | 1997-08-12 | 1999-10-12 | Harris; Roger | Methods and compositions for increasing the anaerobic working capacity in tissue |
| WO2002074302A1 (en) * | 2001-03-15 | 2002-09-26 | Riken | Amino acid compositions for ameliorating liver failure |
| EP1402788A4 (en) * | 2001-06-08 | 2006-03-22 | Riken | Body temperature-raising agent of amino acids for eating or drinking and for medical use |
| US7504376B2 (en) | 1996-08-12 | 2009-03-17 | Natural Alternatives International | Methods and compositions for increasing the anaerobic working capacity in tissues |
| US8329207B2 (en) | 2005-05-23 | 2012-12-11 | Natural Alternatives International, Inc. | Compositions and methods for the sustained release of beta-alanine |
-
1992
- 1992-07-10 JP JP18410792A patent/JPH0624976A/en active Pending
Cited By (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998006278A1 (en) * | 1996-08-12 | 1998-02-19 | Harris, Roger | Methods and compositions for increasing the anaerobic working capacity in tissues |
| US6172098B1 (en) | 1996-08-12 | 2001-01-09 | Roger Harris | Methods and compositions for increasing the anaerobic working in tissues |
| US6426361B2 (en) | 1996-08-12 | 2002-07-30 | Roger Harris | Method and compositions for increasing the anaerobic working capacity in tissues |
| US6680294B2 (en) | 1996-08-12 | 2004-01-20 | Natural Alternatives International | Methods and compositions for increasing the anaerobic working capacity in tissues |
| US8470865B2 (en) | 1996-08-12 | 2013-06-25 | Natural Alternatives International, Inc. | Methods and compositions for increasing the anaerobic working capacity in tissues |
| USRE45947E1 (en) | 1996-08-12 | 2016-03-29 | Natural Alternatives International, Inc. | Method and compositions for increasing the anaerobic working capacity in tissues |
| US7504376B2 (en) | 1996-08-12 | 2009-03-17 | Natural Alternatives International | Methods and compositions for increasing the anaerobic working capacity in tissues |
| US7825084B2 (en) | 1996-08-12 | 2010-11-02 | Natural Alternatives International, Inc. | Methods and compositions for increasing the anaerobic working capacity in tissues |
| US8067381B1 (en) | 1996-08-12 | 2011-11-29 | Natural Alternatives International, Inc. | Methods and compositions for increasing the anaerobic working capacity in tissues |
| US8129422B2 (en) | 1996-08-12 | 2012-03-06 | Natural Alternatives International, Inc. | Methods and compositions for increasing the anaerobic working capacity in tissues |
| US8993610B2 (en) | 1996-08-12 | 2015-03-31 | Natural Alternatives International, Inc. | Methods and compositions for increasing the anaerobic working capacity in tissues |
| US5965596A (en) * | 1997-08-12 | 1999-10-12 | Harris; Roger | Methods and compositions for increasing the anaerobic working capacity in tissue |
| WO2002074302A1 (en) * | 2001-03-15 | 2002-09-26 | Riken | Amino acid compositions for ameliorating liver failure |
| EP1402788A4 (en) * | 2001-06-08 | 2006-03-22 | Riken | Body temperature-raising agent of amino acids for eating or drinking and for medical use |
| KR100852930B1 (en) * | 2001-06-08 | 2008-08-19 | 리가가쿠 겐큐쇼 | Body temperature-raising agent of amino acids for medical use |
| US9668994B2 (en) | 2003-04-10 | 2017-06-06 | Natural Alternatives International, Inc. | Methods and compositions for increasing the anaerobic working capacity in tissues |
| US9907770B2 (en) | 2003-04-10 | 2018-03-06 | Natural Alternatives International, Inc. | Methods and compositions for increasing the anaerobic working capacity in tissues |
| US10881629B2 (en) | 2003-04-10 | 2021-01-05 | Natural Alternatives International, Inc. | Methods and compositions for increasing the anaerobic working capacity in tissues |
| US8394402B2 (en) | 2005-05-23 | 2013-03-12 | Natural Alternatives International, Inc. | Compositions and methods for the sustained release of beta-alanine |
| US8496958B2 (en) | 2005-05-23 | 2013-07-30 | Natural Alternatives International, Inc. | Compositions and methods for the sustained release of beta-alanine |
| US8980307B2 (en) | 2005-05-23 | 2015-03-17 | Natural Alternatives International, Inc. | Compositions and methods for the sustained release of beta-alanine |
| US8329207B2 (en) | 2005-05-23 | 2012-12-11 | Natural Alternatives International, Inc. | Compositions and methods for the sustained release of beta-alanine |
| US9636315B2 (en) | 2005-05-23 | 2017-05-02 | Natural Alternatives International, Inc. | Compositions and methods for the sustained release of beta-alanine |
| US9907769B2 (en) | 2005-05-23 | 2018-03-06 | Natural Alternatives International, Inc. | Compositions and methods for the sustained release of betaalanine |
| US10828274B2 (en) | 2005-05-23 | 2020-11-10 | Natural Alternatives International, Inc. | Compositions and methods for the sustained release of beta-alanine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2873497B2 (en) | Lipid metabolism regulator | |
| US8012926B2 (en) | Amino acid composition and supplementary liquid containing the same | |
| DE2556100C2 (en) | ||
| EP0176094B1 (en) | Parenteral alimentation solution | |
| Maddrey et al. | Effects of keto analogues of essential amino acids in portal-systemic encephalopathy | |
| O'Keefe et al. | The influence of intravenous nutrition on protein dynamics following surgery | |
| JPH0624977A (en) | Antiobestic agent and antilipidemic agent | |
| EP0873754B1 (en) | Amino acid compositions | |
| EP0507872B1 (en) | The use of arginine as an immunostimulator | |
| JPH0811728B2 (en) | Amino acid solution for nutrition infusion, its preparation and use | |
| JP2518692B2 (en) | Muscle maintenance agent, nutrient tonic, infusion agent, nutritional supplement, fatigue recovery agent and lactic acid production regulator | |
| Madden et al. | Tolerance to amino acid mixtures and casein digests given intravenously: glutamic acid responsible for reactions | |
| JPH0624976A (en) | Composition for transfusion solution | |
| EP0457314A1 (en) | Nutrient compositions containing peptides | |
| JP2873493B2 (en) | Blood sugar regulator | |
| EP0502313A2 (en) | Method for insuring adequate intracellular glutathione in tissue | |
| US5122515A (en) | Nutrient composition containing dipeptides and method for administering the same | |
| Eckhardt et al. | Urinary excretion of amino acids following the rapid injection of a solution of amino acids in man | |
| Pennisi et al. | Effects of protein and amino acid diets in chronically uremic and control rats | |
| EP0656178B1 (en) | Nutritional compositions for management of nitrogen metabolism | |
| JP3553992B2 (en) | Metabolic regulator | |
| Metcoff et al. | Protein synthesis, cellular amino acids, and energy levels in CAPD patients. | |
| JP4009682B2 (en) | Adrenaline and noradrenaline secretion promoting composition | |
| US4283392A (en) | Infusion solutions containing amino acids and mineral salts | |
| FR2627386A1 (en) | Compsns. for topical application to eyes - contg. colostrum lactoserum and vitamin=a |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20021224 |